Advertisement

Related Videos

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Advertisement

Advertisement




Apr
25
Today In Oncology
FDA Approves Lu-177 Dotatate for Pediatric Patients With GEP-NETs
AI Model May Help Predict Treatment Responses Select Most Effective Cancer Therapies in Patients With Cancer
In-Hospital Mortality Among Patients With COVID-19 Infection, With or Without Cancer
Imaging Drug to Assist in Detection of Cancerous Tissue Following Lumpectomy Approved
Potential Protective Effects of Aspirin Against Colorectal Cancer
View More 
Advertisement
© 2024 HSP News Service, L.L.C.
Designed by Harborside